Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Hemophilia A - introduction
- Hemophilia A…
- Diagnosis & severity of hemophilia
- Acute severe bleeds
- Hemophilia A: an inherited disease
- Hemophilia A: clinical manifestations and disease progression
- Clinical implications: hemophilic arthropathy
- Current treatment
- Development of inhibitory anti-FVIII antibodies
- Treatment of hemophilia A bleeding episodes
- History of treatments in haemophilia
- Unmet needs still remain in hemophilia treatment
- Innovation is still required
- Hemophilia treatment: past, present and future
- Patient aspirations – HemACTIVE program
- HemActive survey- emerging themes
- Prophylaxis with FVIII therapies
- Adherence to prescribed prophylaxis regimens
- FVIII – the standard of care in hemophilia A
- Rationale for development of recombinant FVIII (1)
- Rationale for development of recombinant FVIII (2)
- Product profiles: standard half-life rFVIII products
- Approaches to extending FVIII half-life
- Fc fusion
- PEGylation
- Potential effect of EHL products on FVIII
- The role of FVIII outside the coagulation cascade
- FVIII replacement & patient’s individual needs
Topics Covered
- Introduction to hemophilia A
- Diagnosis and severity of hemophilia
- Clinical manifestations and disease progression
- Current treatment: on-demand versus prophylactic replacement therapy
- HemACTIVE program identify how disease affects patients daily lives
- New therapeutic options present new possibilities
- FVIII: the standard of care in hemophilia A
- Approaches to extending FVIII half-life
- Adapting FVIII replacement therapy will meet a patient’s individual needs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Krassova, S. (2020, February 27). Hemophilia A [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/HGBB6046.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Snejana Krassova previously worked at Bayer, Novo Nordisk and Biogen Idec.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Snejana Krassova, I'm the head of the Medical Affairs Hematology at Bayer.
I'm immunohematologist by training and been in
the industry of hemophilia for over 17 years.
Today, we're going to talk about hemophilia A
specifically, and the innovations that have been made in this field.
0:22
So, hemophilia A is a genetic deficiency in clotting factor VIII.
As many of you are aware,
it causes increased bleeding and usually affects males.
In the majority of cases,
it's an inherited X-linked recessive trait.
So, it's an X-linked disorder,
the mother is a carrier of the developed gene.
This results in people bleeding longer after any injury,
after bruising, and increased risk of bleeding inside joints or vital organs.
There is no long-term cure yet.
Treatment and prevention of bleeding episodes is done
primarily by replacing the missing clotting factor.
1:02
So, as it's been described,
hemophilia A indeed is a rare disease.
Approximately 400,000 people live with hemophilia-
a majority of women with hemophilia A.
There is also hemophilia B. Hemophilia A happens one in 5,000 male births;
whereas, hemophilia B happens in one of 30,000 male births.
So, again, the major issue is the bleeding into the joints,
muscles, and internal organs.
The classification of hemophilia is based on the factor levels.
In this case, for hemophilia A factor level VIII and the
percentage of the activity of factor VIII in blood.
The severe form is less than one percent;
and then the moderate form,
one to five percent; mild form, 5-40.
The obviously, the normal levels,
it's 50-150 percent in the unaffected individual.
So, again, it's a genetic mutation and it's passed from mother,
the gene on the X chromosome.
So, the daughters can be carriers.
In the very rare cases, a mutation,
what we call lyonization,
the woman can give a mutation also called lyonization.
In this case, a woman can get hemophilia.
This is very, very rare and the woman will have both X chromosomes affected.
As I was saying, it's very rare but it does happen from time to time.
The majority of affected individuals are males.
The incidence of new mutations is about 50 percent,
which means half of the families with
a boy with hemophilia will have a history of hemophilia,
and half of them will not,
which would be out of two and quite unexpected for the parents.